MGX
MGX
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$23K
Insider Sales
25
$94K
Total Volume
$118K
35 transactions
Net Activity
$71K
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 80% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
P - Purchase Insiders
$400.00M total
Thomas Brian C.
Dir
$31K total
Irish Jian
See Remarks
$27K total
Reid Laurence
Dir
$23K total
Wapnick Pamela
CFO
$23K total
Quick Actions
MGX has an insider buy conviction of 20%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at MGX (MGX) engaged in a total of 35 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 25 were sales. The total volume of insider trading reached $118K.
The net insider activity for MGX shows a net selling bias of $71K. This activity represents a 20% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 20.0K shares valued at $400.00M on Sep 9, 2026.
MGX Forecast — Price Target — Prediction for 2027
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates
Metagenomi Therapeutics (NasdaqGS:MGX) Stock Forecast & Analyst Predictions
A potential one-time hemophilia A treatment is planned for a global trial in 2027, pending regulatory clearance.
symbol__ Stock Quote Price and Forecast
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?
FAQs About MGX Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for MGX.